4142:TPE
Adimmune Corp
NT$15.85
arrow_downward
-1.86%(-0.30) 1D
Nov 19, 1:30:08 PM GMT+8 · TWD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4142...
Open
NT$16.20
High
NT$16.25
Low
NT$15.70
Mkt. cap
6.81B
Avg. vol.
1.09M
Volume
1.60M
P/E ratio
91.85
52-wk high
NT$21.50
52-wk low
NT$15.65
EPS
NT$0.17
Shares outstanding
235.29M
No. of employees
564
Open
NT$16.20
High
NT$16.25
Low
NT$15.70
Mkt. cap
6.81B
Avg. vol.
1.09M
Volume
1.60M
P/E ratio
91.85
52-wk high
NT$21.50
52-wk low
NT$15.65
EPS
NT$0.17
Shares outstanding
235.29M
No. of employees
564
News stories
From web sources and news partners
Yahoo Finance
·
18 minutes ago
Stock market today: Dow, S&P 500, Nasdaq futures rise ahead of historic Anthropic IPO
FOREX.com
·
3 hours ago
S&P 500 Grasps At Support as Surging Hike Odds, Treasury Yields Threaten Larger Turn
BigGo Finance
·
4 hours ago
UBS Sets S&P 500 Target of 8,200 by End-2027, Implying Roughly 12% Upside, But Cuts Rating to Neutral
TradingView
·
3 hours ago
Stock Market: Will S&P 500 Open Up or Down Today?
Profile
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
About Adimmune Corp
CEO-
Employees564
Founded1965
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteadimmune.com.tw